Firstly, we evaluated the tumor killing effect by selecting CD19, CD20, and CD22 simultaneously antigen-expressing B-ALL cells (NALM-6) as well as primary cells (Fig. 3B). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.